Variance of HRD From Paired Ovarian Cancer
NCT05069818 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2021-10-06
Summary
Homologous recombination deficiency (HRD) is an important biomarker of poly (ADP-ribose) polymerase inhibitor (PARPi) in patients with high-grade serous ovarian cancer (HGSOC). The stability of HRD in the recurrent HGSOC and its primary pair remains unknown.
Conditions
- Ovarian Cancer
- HRD
- Platinum-sensitive Ovarian Cancer
Sponsors & Collaborators
-
Xiaoxiang Chen
lead OTHER
Principal Investigators
-
Xiaoxiang Chen Chen, MD,PhD · Jiangsu Cancer Institute & Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-31
- Primary Completion
- 2022-10-31
- Completion
- 2022-12-31
Countries
- China
Study Locations
More Related Trials
-
Exploratory Study on the Correlation Between HRD Score and PARPi Efficacy Based on Chinese Ovarian Cancer Patients
NCT06622798 ·Status: RECRUITING
-
Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer
NCT04991051 ·Status: COMPLETED
-
Functional Analysis of BRCAness
NCT04780945 ·Status: TERMINATED ·Phase: PHASE2
-
The Clinical Markers for PARP Inhibitors-related Efficacy in Ovarian Cancer
NCT04582552 ·Status: UNKNOWN
-
Design and Validation of Plasma Proteins and Cytokine Panels to Identify Markers Associated With Response to Niraparib as Maintenance Treatment After First-line Platinum-based Regimen in Patients With Advanced Ovarian Cancer
NCT07059676 ·Status: NOT_YET_RECRUITING
-
Pathogenic Variants in Homologous Recombination Repair Genes in Patients With Epithelial Ovarian Cancer
NCT04716374 ·Status: COMPLETED
-
A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
NCT05460000 ·Status: RECRUITING ·Phase: PHASE2
-
Patient Preferences for Precision Medicine: Determining Optimal Patient Quality of Life Using PARPi's
NCT06751303 ·Status: RECRUITING ·Phase: NA
-
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
NCT06964165 ·Status: TERMINATED ·Phase: PHASE2
-
A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib
NCT06037213 ·Status: UNKNOWN
-
A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer
NCT03509636 ·Status: COMPLETED ·Phase: PHASE1
-
Prospective Cohort Study for Validation of Predictive Immune Biomarkers of Response to PAPR Inhibitors
NCT05640024 ·Status: RECRUITING
-
Homologous Recombination Inquiry Through Ovarian Malignancy Investigations
NCT03159572 ·Status: COMPLETED
-
Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.
NCT02341118 ·Status: TERMINATED
-
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
NCT06141265 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
NCT02354586 ·Status: COMPLETED ·Phase: PHASE2
-
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
NCT03933761 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT05613088 ·Status: COMPLETED ·Phase: PHASE2
-
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
NCT05187208 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes
NCT03967938 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands
NCT07039552 ·Status: RECRUITING
-
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
NCT03759600 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status
NCT02983799 ·Status: COMPLETED ·Phase: PHASE2
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT03586661 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1